New drugs for the treatment of fatty liver diseases (NASH)
|Coordinator||Inorbit Therapeutics AB|
|Funding from Vinnova||SEK 300 000|
|Project duration||May 2018 - November 2018|
Purpose and goal
It was the aim of the project to further mature InorbitTX´s FXR project for the treatment of Non-Alcoholic Steato-Hepatitis (NASH) by generating novel FXR agonists to profile them as potential new and safer drugs. The project further aimed to generate test data supporting a patent application describing the whole chemical series.
Expected results and effects
Three novel designed molecules were synthesised and tested against InorbitTX´s lead compound. One appeared of particular interest as it showed a very high potential to stimulate the FXR receptor in an in vitro assay. That particular compound and the original lead compound were further evaluated in a series of in vitro tests. The tests performed showed data supportive to pursue the compounds to more elaborative testing and evaluation as potential new medicines.
Planned approach and implementation
The studies that were performed were designed and carried out in collaboration with leading contract research organisations (CRO). The data obtained were analysed in collaboration with the researchers in the CRO´s and other external experts.